
Foghorn Therapeutics (FHTX) Stock Forecast & Price Target
Foghorn Therapeutics (FHTX) Analyst Ratings
Bulls say
Foghorn Therapeutics is positioned to capitalize on the growing interest in precision medicines for cancer treatments, with a seasoned team and strong pre-clinical data for their lead program FHD-909. They have a strategic partnership with Eli Lilly for development and commercialization of their therapies, providing a potential source of revenue and validation of their approach. However, they face competition in the targeted oncology space and must successfully navigate clinical trials and regulatory approvals to achieve success.
Bears say
Foghorn Therapeutics is a clinical-stage biotechnology company with a focus on developing precision therapeutics for serious diseases by targeting the chromatin regulatory system. However, the company carries significant risks due to the reliance on its patent protection for market exclusivity and regulatory approvals for its candidates. Its flagship program, FHD-909, has shown encouraging pre-clinical data, but there are concerns over its selective targeting strategy and potential overlap with other known mutations in NSCLC. Additionally, competition from companies like Arvinas, IDEAYA Biosciences, Kymera Therapeutics, and Nurix Therapeutics further adds to the negative outlook on Foghorn's stock.
This aggregate rating is based on analysts' research of Foghorn Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Foghorn Therapeutics (FHTX) Analyst Forecast & Price Prediction
Start investing in Foghorn Therapeutics (FHTX)
Order type
Buy in
Order amount
Est. shares
0 shares